Back to results
US 2016/0095872 A1Published application
Therapeutic Compositions Comprising Imidazole and Imidazolium Compounds
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
Claims30
A method of treating knee pain comprising orally administering a dosage form to a mammal in need thereof, wherein the dosage form comprises:
- in an amount that is less than 0.1% w/w, and greater than 0% w/w;
- or
- in an amount that is less than 0.1% w/w, and greater than 0% w/w;
- wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;
- wherein each A is independently an acidic functional group;
- wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4%.
3 more elements
A method of treating knee pain comprising orally administering a dosage form to a human being suffering from knee pain, wherein the dosage form comprises:
- a) zoledronic acid;
- or
- b) one of the following:
- 1) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- 2) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- or
- 3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
- wherein the dosage form is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
- wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2;
- and
- wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4%.
10 more elements
A pharmaceutical dosage form comprising:
- a) zoledronic acid;
- or
- b) one of the following:
- 1) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- 2) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- or
- 3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
- wherein the dosage form is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
- wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2;
- and
- wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 4% in a human being.
10 more elements
Dependencies are inferred from the claim text.